Tranexamic acid

Generic Name
Tranexamic acid
Brand Names
Cyklokapron, Lysteda
Drug Type
Small Molecule
Chemical Formula
C8H15NO2
CAS Number
1197-18-8
Unique Ingredient Identifier
6T84R30KC1
Background

Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.

It was first patented in 1957 and received its initial US approval in 1986.

Indication

Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleeding following tooth extraction.

Associated Conditions
Bleeding, Heavy Menstrual Bleeding, Hereditary Angioedema (HAE)
Associated Therapies
-
Clinical Trials
Related News

Prevention of Postoperative Bleeding in Subcapital Femoral Fractures

First Posted Date
2014-05-30
Last Posted Date
2016-09-20
Lead Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Target Recruit Count
161
Registration Number
NCT02150720
Locations
🇪🇸

Hospital Clinic, Barcelona, Spain

🇪🇸

Parc Taulí, Sabadell, Barcelona, Spain

🇪🇸

Hospital Universitari Mútua Terrassa, Terrassa, Barcelona, Spain

and more 3 locations

Rotational Thromboelastography Study in Tranexamic Acid and Colloid Infusion

First Posted Date
2014-05-23
Last Posted Date
2015-06-17
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
60
Registration Number
NCT02146456
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of

Effect of Tranexamic Acid in Ruptured Abdominal Aortic Aneurysms

Phase 3
Completed
Conditions
Abdominal Aortic Aneurysms
Interventions
Drug: Tranexamic Acid
First Posted Date
2014-04-29
Last Posted Date
2020-03-18
Lead Sponsor
Saskatchewan Health Authority - Regina Area
Target Recruit Count
9
Registration Number
NCT02125890
Locations
🇨🇦

Jagadish Rao, Regina, Saskatchewan, Canada

Tranexamic Acid Effect on Platelet Aggregation Following Infant Cardiopulmonary Bypass

Phase 4
Withdrawn
Conditions
Heart Defect, Congenital
Interventions
Drug: Tranexamic Acid
Drug: placebo
First Posted Date
2014-04-24
Last Posted Date
2016-11-25
Lead Sponsor
Emory University
Registration Number
NCT02122679
Locations
🇺🇸

Children's Healthcare of Atlanta, Atlanta, Georgia, United States

The Efficacy and Safety of Using Tranexamic Acid by Different Means to Reduce Blood Loss During Total Knee Replacement

Phase 4
Completed
Conditions
Blood Loss
Interventions
Drug: Tranexamic acid
First Posted Date
2014-04-17
Last Posted Date
2016-03-04
Lead Sponsor
Xijing Hospital
Target Recruit Count
150
Registration Number
NCT02117128
Locations
🇨🇳

Xijing hospital, Xi'an, Shaanxi, China

The Effect of Tranexamic Acid for Total Hip Arthroplasty

First Posted Date
2014-03-21
Last Posted Date
2014-03-26
Lead Sponsor
TC Erciyes University
Target Recruit Count
60
Registration Number
NCT02094066
Locations
🇹🇷

Erciyes univercity medicine faculty, Kayseri, Turkey

Study of Tranexamic Acid During Air and Ground Medical Prehospital Transport Trial (STAAMP Trial)

First Posted Date
2014-03-13
Last Posted Date
2020-09-10
Lead Sponsor
Jason Sperry
Target Recruit Count
903
Registration Number
NCT02086500
Locations
🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Tranexamic Acid in Orthopaedic Trauma Surgery

Not Applicable
Conditions
Blood Loss
Trauma
Fracture
Surgery
Interventions
Drug: Tranexamic Acid
First Posted Date
2014-03-06
Last Posted Date
2018-07-11
Lead Sponsor
University of Tennessee
Target Recruit Count
101
Registration Number
NCT02080494
Locations
🇺🇸

Erlanger Health System, Chattanooga, Tennessee, United States

Effectiveness Study of the Drug Tranexamic Acid to Reduce Post-surgery Blood Loss in Spinal Surgery

First Posted Date
2014-02-14
Last Posted Date
2017-06-08
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
29
Registration Number
NCT02063035
Locations
🇺🇸

Massachusetts General Hospital Orthopedic Spine, Boston, Massachusetts, United States

Efficacy of Intravenous Versus Topical Tranexamic Acid in Primary Total Hip Arthroplasty

Not Applicable
Completed
Conditions
Osteoarthritis
Interventions
Drug: Tranexamic Acid
First Posted Date
2014-02-06
Last Posted Date
2016-03-10
Lead Sponsor
Lawson Health Research Institute
Target Recruit Count
149
Registration Number
NCT02056444
Locations
🇨🇦

London Health Sciences Centre, University Hospital, London, Ontario, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy